Literature DB >> 22349750

Calcium channel blockers are inadequate for malignant hyperthermia crisis.

Takako Migita1, Keiko Mukaida, Toshimichi Yasuda, Hiroshi Hamada, Masashi Kawamoto.   

Abstract

PURPOSE: Malignant hyperthermia (MH) results from disordered calcium (Ca(2+)) homeostasis in skeletal muscle during general anesthesia. Although Ca(2+) channel blockers may be given to treat the tachycardia and circulatory instability, coadministration of Ca(2+) channel blockers and dantrolene is contraindicated during MH crisis. We evaluated the effect of Ca(2+) channel blockers on Ca(2+) homeostasis and their interactions with dantrolene in human skeletal muscle.
METHODS: Human skeletal muscle samples were obtained by biopsy and divided into two groups according to the results of the Ca(2+)-induced Ca(2+) release rate test. Differentiated myotubes were labeled with Fura-2, and changes in the 340/380-nm ratio were used to calculate changes in Ca(2+) concentration following nifedipine treatment in the absence or presence of dantrolene.
RESULTS: Nifedipine induced a transient increase in the intracellular Ca(2+) concentration ([Ca(2+)](i)) in a dose-dependent manner. The half-maximal concentration (EC(50)) for nifedipine was 0.718 ± 0.329 μM in the accelerated group and 1.389 ± 0.482 μM in the nonaccelerated group (P = 0.009). The addition of 50 μM dantrolene attenuated by 15.4% the increase in [Ca(2+)](i) caused by the 0.5 μM nifedipine.
CONCLUSION: Ca(2+) channel blockers led to increased [Ca(2+)](i) in human skeletal muscle cells. The increase is thus scarcely affected by dantrolene treatment. Data provide a greater physiologic basis for avoiding the use of Ca(2+) channel blockers during MH crisis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22349750     DOI: 10.1007/s00540-012-1347-0

Source DB:  PubMed          Journal:  J Anesth        ISSN: 0913-8668            Impact factor:   2.078


  31 in total

Review 1.  Malignant hyperthermia: advances in clinical management and diagnosis.

Authors:  P M Hopkins
Journal:  Br J Anaesth       Date:  2000-07       Impact factor: 9.166

2.  Serine residue in the IIIS5-S6 linker of the L-type Ca2+ channel alpha 1C subunit is the critical determinant of the action of dihydropyridine Ca2+ channel agonists.

Authors:  S Yamaguchi; Y Okamura; T Nagao; S Adachi-Akahane
Journal:  J Biol Chem       Date:  2000-12-29       Impact factor: 5.157

3.  Fulminant-type malignant hyperthermia in Japan: cumulative analysis of 383 cases.

Authors:  Takako Migita; Keiko Mukaida; Masashi Kawamoto; Masako Kobayashi; Osafumi Yuge
Journal:  J Anesth       Date:  2007-05-30       Impact factor: 2.078

Review 4.  Pharmacological differences between calcium antagonists.

Authors:  L H Opie
Journal:  Eur Heart J       Date:  1997-01       Impact factor: 29.983

Review 5.  Structural basis of drug binding to L Ca2+ channels.

Authors:  J Striessnig; M Grabner; J Mitterdorfer; S Hering; M J Sinnegger; H Glossmann
Journal:  Trends Pharmacol Sci       Date:  1998-03       Impact factor: 14.819

6.  Malignant hyperthermia in Japan: mutation screening of the entire ryanodine receptor type 1 gene coding region by direct sequencing.

Authors:  Carlos A Ibarra M; Shiwen Wu; Kumiko Murayama; Narihiro Minami; Yasuko Ichihara; Hirosato Kikuchi; Satoru Noguchi; Yukiko K Hayashi; Ryoichi Ochiai; Ichizo Nishino
Journal:  Anesthesiology       Date:  2006-06       Impact factor: 7.892

7.  Conformational activation of Ca2+ entry by depolarization of skeletal myotubes.

Authors:  Gennady Cherednichenko; Alanna M Hurne; James D Fessenden; Eun Hui Lee; Paul D Allen; Kurt G Beam; Isaac N Pessah
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-25       Impact factor: 11.205

8.  Hyperkalemia and cardiovascular collapse after verapamil and dantrolene administration in swine.

Authors:  L S Saltzman; R A Kates; B C Corke; E A Norfleet; K R Heath
Journal:  Anesth Analg       Date:  1984-05       Impact factor: 5.108

9.  The skeletal L-type Ca(2+) current is a major contributor to excitation-coupled Ca(2+) entry.

Authors:  Roger A Bannister; Isaac N Pessah; Kurt G Beam
Journal:  J Gen Physiol       Date:  2009-01       Impact factor: 4.086

Review 10.  Malignant hyperthermia.

Authors:  Henry Rosenberg; Mark Davis; Danielle James; Neil Pollock; Kathryn Stowell
Journal:  Orphanet J Rare Dis       Date:  2007-04-24       Impact factor: 4.123

View more
  3 in total

Review 1.  [Malignant hyperthermia].

Authors:  T Metterlein; F Schuster; B M Graf; M Anetseder
Journal:  Anaesthesist       Date:  2014-12       Impact factor: 1.041

Review 2.  Anesthetic Management of the Hypertensive Patient: Part II.

Authors:  Russell Yancey
Journal:  Anesth Prog       Date:  2018

3.  JSA guideline for the management of malignant hyperthermia crisis 2016.

Authors: 
Journal:  J Anesth       Date:  2017-02-28       Impact factor: 2.078

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.